FLIRT
Etude de deux stratégies d’administration du rituximab (IV et SC) en première ligne chez des patients atteints d'un Lymphome Folliculaire de faible masse tumorale (phase III)Publications 2023
Lysa
2023_LYSA_Randomized Phase III Trial Evaluating Sub-Cutaneous Rituximab for the First Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol . 2023 Apr 18;JCO2202327. doi: 10.1200/JCO.22.02327.
En savoir plus
Poster FLIRT | EHA 2022 |
---|---|
G. Cartron | Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study. |
Poster FLIRT | ASCO 2022 |
---|---|
G. Cartron | Sub- Cutaneous Rituximab Induction Followed by Short Rituximab Maintenance Improves Progression-Free Survival in Patients with Low-Tumor Burden Follicular Lymphoma. Final Results of FLIRT Phase III Trial, a LYSA Study. |
Publications 2021
Lysa
2021_LYSA_Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche
Blood . 2021 Jul 8;138(1):57-70.
En savoir plus
Lysa
2021_LYSA_Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape
Immunity . 2021 Aug 10;54(8):1901.
En savoir plus